A comparative study on ITOD/CHOP and CHOP regimens for treatment of non-Hodgkin's lymphoma

Objective To compare the therapeutic response and safety of ITOD(ifosfamide,pirarubicin,vindesine,dexamethasone)/CHOP(cyclophophamide,doxorubicin vincristine,prednisone) regimen and CHOP regimen in the treatment of non-Hodgkin's lymphoma.Methods One hundred and one non-Hodgkin's lymphoma patients were enrolled in this study.Patients were divided into two groups.One group was treated with sequential ITOD/CHOP regimen and the other was treated with classic CHOP regimen(control group).Complete remission(CR) rate,partial remission(PR) rate,no response(NR) rate,1-,3-,and 5-year survival rates and chemotherapy adverse effects were analyzed.Results CR rate and overall response rate in sequential ITOD/CHOP group were higher than that of CHOP control group;PR rate was slightly lower than that in CHOP control group(33.3% vs 34.8%,P0.05).No statistical significant differences were seen between the 1-,3-,and 5-year survival rates in sequential ITOD/CHOP group(86.9%,65.2% and 43.5%,respectively) and in control group(85.9%,71.6% and 50%,respectively).Multiple variance regression analysis showed that clinical stage and presence of big mass were correlated with therapeutic regimen and response rate(P0.01).Altogether 539 courses of chemotherapy were afforded to 101 patients,liver and renal toxicity,myelosuppression,gastrointestinal adverse effects and alopecia were the dominant adverse effects.No significant differences in the occurrence of adverse effects were seen between the two groups except cadiotoxicity,which was significantly higher in control group(41.8% vs 24.9%,P0.01).Conclusions Sequential ITOD/CHOP regimen is an effective and safe chemotherapy regimen for treating B cell malignant lymphoma,response rate and survival rate were not significantly different from the classic CHOP regimen,while its cardiotoxicity was significantly lower than that of classic CHOP regimen.